You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

Article metrics

Article menu

Download PDFPDF

XML
Oncolytic and local immunotherapy
Original research
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

 

Online download statistics by month:

Online download statistics by month: August 2020 to March 2024

AbstractFullPdf
Aug 2020428429263
Sep 202016716764
Oct 202016816838
Nov 20204950114
Dec 202020220246
Jan 2021838237
Feb 2021818145
Mar 202110310451
Apr 2021999926
May 2021535320
Jun 2021585823
Jul 2021525218
Aug 2021343625
Sep 2021606043
Oct 2021777850
Nov 2021606046
Dec 2021525225
Jan 2022525425
Feb 2022404014
Mar 2022646630
Apr 2022697941
May 2022444415
Jun 2022606123
Jul 2022484911
Aug 2022545424
Sep 2022606054
Oct 2022555724
Nov 2022646434
Dec 2022474728
Jan 2023454620
Feb 2023888830
Mar 2023575828
Apr 2023717118
May 2023606118
Jun 202328285
Jul 2023393917
Aug 2023313112
Sep 2023383821
Oct 202315115113
Nov 202324824812
Dec 2023373710
Jan 2024404110
Feb 2024323215
Mar 2024394429
Total348735191515